Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Wake Forest University Health Sciences
AstraZeneca
Shanghai Henlius Biotech
Mayo Clinic
AstraZeneca
G1 Therapeutics, Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
AstraZeneca
BioNTech SE
EpicentRx, Inc.
BeiGene
AstraZeneca
Columbia University
Hoosier Cancer Research Network
Weill Medical College of Cornell University
NantCell, Inc.
Hoosier Cancer Research Network
EMD Serono
Hoffmann-La Roche
Eastern Cooperative Oncology Group
University of Washington
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
NYU Langone Health
Hoffmann-La Roche
Merck Sharp & Dohme LLC
RTOG Foundation, Inc.
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Mereo BioPharma
G1 Therapeutics, Inc.
Bristol-Myers Squibb
AbbVie
Abramson Cancer Center at Penn Medicine
Hoosier Cancer Research Network
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Milton S. Hershey Medical Center
SWOG Cancer Research Network